In the Federal Register, Feb 9, 1973, the Food and Drug Administration (FDA) published a notice to withdraw from the market certain antitussive combinations. Named in the withdrawal notice are the following preparations:
Novrad With ASA
Coricidin With Codeine Phosphate
Phenergan Expectorant With Codeine
Phenergan Expectorant
Phenergan VC Expectorant
Phenergan VC Expectorant With Codeine
Pediatric Phenergan Expectorant
Phenergan Expectorant Troches
Phenergan Expectorant Troches With Codeine
Dimetane Expectorant
Dimetane Expectorant-DC
Omni-Tuss suspension
Tussionex tablets
Ulogesic tablets
Ulominic Syrup
Coditrate Syrup
Methajade liquid
Thephorin Expectorant
Actifed-C Expectorant
Clistin Expectorant
Tuss-Ornade liquid
Tuss-Ornade Spansules
Benylin Expectorant
Ambenyl Expectorant
Cothera Compound
Pyribenzamine Expectorant
Pyribenzamine Expectorant With Codeine and Ephedrine
However, other products of similar compositions will also be affected even though they are not specifically cited.
The FDA is basing this action on regulations established by the 1962 Harris-Kefauver amendments to the Food, Drug, and Cosmetic Act of 1938 and on the National Academy